Dogwood Therapeutics, Inc. Annual report pursuant to Section 13 and 15(d)

Accrued Expenses (Tables)

12 Months Ended

Dec. 31, 2022


	December 31,		December 31,
	2022		2021
Accrued compensation	$	159,704	$	532,678
Accrued interest on preferred members’ interests		188,085		188,085
Accrued clinical research costs		78,349		138,522
Accrued director fees		31,000		31,000
Accrued professional fees		11,600		24,100
Other miscellaneous accrued expenses		1,360		7,375
	$	470,098	$	921,760